Harnessing Synthetic Lethal Interactions for Personalized Medicine

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Synthetic lethality (SL) describes conditions where simultaneous gene mutations are lethal, but individual mutations are not.
• Targeting SL partners of mutated cancer genes offers a strategy to selectively eliminate cancer cells while sparing normal cells.
• FDA-approved PARP inhibitors for BRCA1/2-mutated tumors exemplify the clinical success of the SL concept.

Purpose of the Study:

• To review the applications of the synthetic lethality concept in translational cancer medicine over the last five years.
• To highlight recent advancements in exploiting SL interactions for drug development and patient stratification.
• To discuss challenges and future directions in the field of synthetic lethality for cancer therapy.

Main Methods:

• Literature review of studies published in the past five years focusing on synthetic lethality in cancer.
• Analysis of research on drug combinations, biomarker identification, and patient stratification using SL principles.
• Synthesis of findings related to overcoming tumor resistance and enhancing targeted and immunotherapy efficacy.

Main Results:

• Exploitation of SL for novel drug combinations to overcome tumor resistance.
• Identification of prognostic and predictive biomarkers through synthetic lethality screens.
• Application of SL interactions for patient stratification in targeted therapy and immunotherapy.

Conclusions:

• The synthetic lethality concept has significant translational potential in oncology.
• Recent advancements demonstrate its utility in developing innovative cancer treatments and personalized medicine approaches.
• Further research is needed to address challenges and fully realize the therapeutic promise of synthetic lethality.